Skip to main content
ABOS
NASDAQ Life Sciences

Acumen Pharmaceuticals Reports Substantial Increase in Full-Year 2025 Net Loss Amidst Pipeline Progress

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$2.66
Mkt Cap
$159.308M
52W Low
$0.855
52W High
$3.6
52W Position info
211% above low
Off High info
26% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

ABOS has more than doubled off its 52-week low of $0.855.

Summary

Acumen Pharmaceuticals reported a net loss of $121.3 million for 2025, an increase from the prior year, with cash reserves expected to last into early 2027, supported by a recent private placement, as it progresses its Alzheimer's disease pipeline.


Key Events · Earnings and Guidance · ABOS

  • Increased Full-Year Net Loss

    The company reported a net loss of $121.3 million for the year ended December 31, 2025, a significant increase from $102.3 million in 2024.

  • Higher Loss Per Share

    Diluted net loss per common share for 2025 was $(2.00), compared to $(1.71) in the previous year.

  • Extended Cash Runway

    Cash, cash equivalents, and marketable securities totaled $116.9 million as of December 31, 2025, which, including a recent $35.75 million private placement, is expected to fund operations into early 2027.

  • Key Pipeline Milestones Ahead

    Topline results for the Phase 2 ALTITUDE-AD study are anticipated in late 2026, and an IND filing for the Enhanced Brain Delivery (EBD) program is targeted for mid-2027.


Analysis · ABOS · Life Sciences

Acumen Pharmaceuticals reported a significant increase in its net loss for the full year 2025, reaching $121.3 million, up from $102.3 million in 2024. This substantial loss, alongside an increased EPS loss of $(2.00), highlights the company's high burn rate as it advances its clinical programs. However, the company's cash, cash equivalents, and marketable securities of $116.9 million as of December 31, 2025, bolstered by a recent $35.75 million private placement, are projected to fund operations into early 2027. This extended cash runway is critical for a clinical-stage biotech, providing stability despite the large losses. Investors will be closely watching the upcoming topline results for the Phase 2 ALTITUDE-AD study in late 2026 and the IND filing for the Enhanced Brain Delivery program in mid-2027, as these milestones are crucial for future valuation.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 44.9% of the 1410 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ABOS was trading at $2.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $159.3M. The 52-week trading range was $0.86 to $3.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ABOS - Latest Insights

ABOS
Nov 05, 2026, 4:01 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.2143
Real-time Price: $0.2094 info
Change: -$0.0049 (-2%) info
Market Cap: $15.464M info
ABOS
Oct 30, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
10
Price at Filing: $1.40
Real-time Price: $0.2094 info
Change: -$1.19 (-85%) info
Market Cap: $15.464M info
ABOS
Oct 26, 2026, 4:21 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $2.29
Real-time Price: $0.2094 info
Change: -$2.08 (-91%) info
Market Cap: $15.464M info
ABOS
Oct 26, 2026, 7:09 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.02
Real-time Price: $0.2094 info
Change: -$1.81 (-90%) info
Market Cap: $15.464M info
ABOS
Oct 26, 2026, 7:01 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $2.04
Real-time Price: $0.2094 info
Change: -$1.83 (-90%) info
Market Cap: $15.464M info